Figure 10 | Scientific Reports

Figure 10

From: A Notch signaling-related lncRNA signature for predicting prognosis and therapeutic response in clear cell renal cell carcinoma

Figure 10The alternative text for this image may have been generated using AI.

Comparing the estimated half-maximal inhibitory concentration (IC50) of Gefitinib, Sorafenib, Sunitinib, Temsirolimus, Erlotinib, Cisplatin, Gemcitabine, Docetaxel, Rapamycin, Lapatinib, Axitinib, and Pazopanib between the high- and low-risk groups in the total TCGA dataset.

Back to article page